EGFR and non-small cell lung carcinoma: A multi-institutional study in the United States also demonstrated that the use of upfront SRS or WBRT is associated with better OS (46 and 30 months, respectively) in patients with EGFR-mutant NSCLC with brain metastases compared to EGFR-TKI monotherapy [20].